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Mechanisms of Retinoid Resistance in Leukemic Cells: Possible Role of Cytochrome P450 and P-Glycoprotein
By Masahiro Kizaki, Hironori Ueno, Yasushi Yamazoe, Miki Shimada, Nobuyuki Takayama, Akihiro Muto, Hiromichi Matsushita, Hideaki Nakajima, Minoru Morikawa, H. Phillip Koeffler, and Yasuo lkeda Retinoic acid (RA) regulates the differentiation and proliferation of a wide variety of different cell types and all-trans RA induces complete remission in a high proportion of patients with acute promyelocytic leukemia (APL). However, clinical resistance t o retinoids may develop and poses a serious problem for differentiation-inducing therapy. We studied the effects of RA in combination with a cytochrome P450 inhibitor (clotrimazole) and a P-glycoprotein antagonist (verapamil) on cell growth and differentiation of RA-resistant HL-60 cells and fresh RA-resistant leukemic cells from two APL patients. RA-resistant HL-60 cells and APL cells differentiated t o mature granulocytes when cultured with all-trans RA and either clotrimazole and verapamil but not with either of the agents alone. These findings were confirmed in these cells by their increased expression of C D l l b antigen and migration-inhibitory factor-related protein-8/14 mRNAs and ETINOIDS AND THEIR active metabolites, including retinoic acid (RA), play an important role in morphogenesis, differentiation, and homeostasis.'.' RA influences epithelial cell growth and differentiation,' suppresses malignant tran~formation,~ and induces differentiation of mouse embryonal carcinoma cells in vitro. 4 In the hematopoietic system, RA inhibits the clonal growth of fresh leukemic cells and cell lines from patients with acute myelogenous leukemia in vitro.' Moreover, RA induces terminal differentiation of HL-60 cells as well as fresh acute promyelocytic leukemia (APL) cells in Recent clinical studies have shown that a high proportion of patients with APL achieve complete remission after treatment with all-trans RA (ATRA) in Nevertheless, most patients that received continuous treatment with RA relapsed and developed RA-resistant disease." Clinical resistance to RA poses a serious problem for differentiationinducing therapy. We have reported that the combination of 9-cis RA and ATRA was an effective inducer of differentiation of RA-resistant HL-60 cells"; however, the detailed mechanisms for this development of RA resistance by APL cells is still unclear.
Because plasma concentrations of RA progressively decreased with continuous treatment with ATRA,I3 one mechanism for RA resistance is an alteration in metabolism of the drug. Review of retinoid metabolism suggest that several key points exist in which retinoid resistance might OCCUT.'~ RA is hydroxylated at the cyclohexenyl ring to form a 4-hydroxy-RA metabolite by a cytochrome P450-dependent mono-oxygenase system.15 Thus, intracellular RA levels in myeloid leukemic cells may decrease as the cells increase their expression of cytochrome P450 enzymes. Another possibility is the induction of expression of P-glycoprotein, which is an energy-dependent drug efflux pump that decreases intracellular drug accumulation. P-glycoprotein, which is encoded by the multidrug-resistance1 (MDR1) gene, is overexpressed in a variety of tumor cells, and studies have shown a correlation of expression of P-glycoprotein/ R Blood, Vol 87, No 2 (January 15). 1996: pp 725-733 decreased levels of c-myc mRNA. These combinations also markedly decreased the number of viable cells and inhibited cellular proliferation. After isolation of microsomes, measurements showed that levels of cytochrome P450 activities in both wild-type and RA-resistant HL-60 cells were almost comparable. Moreover, expression of the CYPlAl-type cytochrome P450 gene could not be detected in either cell type. However, RA-resistant HL-60 cells and APL cells, but not RAsensitive HL-60 cells and APL cells, expressed multidrugresistance-l gene transcripts. Taken together, acquired resistance t o RA may be explained in part by drug metabolism in leukemic cells. Possible mechanisms for accelerated clearance of RA include the induction of non-CYPlAl cytochrome P450 enzymes and P-glycoprotein. MDRl with the clinical resistance to chem~therapy.'~.'' Taken together, either of these pathways might be important in development of retinoid resistance in leukemic cells. Therefore, to address the possible role of cytochrome P450 and P-glycoprotein in RA resistance of leukemic cells, we studied the effects of either a cytochrome P450 inhibitor or a P-glycoprotein antagonist in combination with ATRA on cell growth and differentiation of RA-resistant HL-60 cells and fresh retinoid-resistant leukemic cells from two patients with APL.
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KlZAKl ET AL serum." After obtaining written informed consent following institutional guidelines, bone marrow samples were obtained from five patients with APL includmg two RA-resistant patients. Mononuclear cells were separated over Ficoll-Hypaque (density, 1.077; Sigma Chemical CO, St Louis, MO) and washed twice with phosphatebuffered saline (GIBCO BRL, Gaithersberg, MD). Cells were maintained in RPMI-1640 medium (GIBCO BRL) with 10% fetal bovine serum (Cytosystems, New South Wales, Australia). ATRA (10." mom; Sigma) was always added to the culture medium for the maintenance of RA-resistant HL-60 cells."
At least 4 days before each experiment, the cells were washed with phosphate-buffered saline; then retinoid and chemicals were added to the medium. Cells (2 X 1OS/mL) were suspended with test materials at appropriate concentrations. After incubation for 4 days, cells were harvested and examined for induction of differentiation by morphology. The morphology of the cells was evaluated from cytospin slide preparations stained with Wright-Giemsa.
HepG2 (human hepatoblastoma) cells were obtained from the American Type Culture Collection (Rockville, MD) and maintained in minimum essential medium with nonessential amino acids and sodium pyruvate (GIBCO BRL). A 200-fold trimetrexate-resistant subline of human leukemia cell lines MOLT-3, MOLT-3/TMQ200, was a gift from Dr T. Ohnuma (Mount Sinai School of Medicine. New York, NY)'" and was maintained in RPM1 1640 medium with 10% fetal bovine serum.
Chemicals. ATRA was dissolved in 100% ethanol to a stock concentration of 1 mmoVL, was stored at -20"C, and was protected from light. The cytochrome P450 inhibitor (clotrimazole; gift from Bayel Yakuhin, Ltd, Tokyo, Japan), P-glycoprotein antagonist (verapamil; Sigma), and 3-methylcholanthrene (Sigma) were dissolved in 100% ethanol. In each experiment, controls were run using the same concentration of ethanol as was present in the experimental plates, and this concentration of dilutant had no effect on proliferation and differentiation of cells.
Assaysfiw cellularproliferarion. Cellular proliferation was measured by cell viability and nonradioactive cell proliferation assay system ( M m assay; Boehringer Mannheim, Tokyo, Japan). Cells (2 X 10') were incubated with ATRA with or without either the cytochrome P450 inhibitor or P-glycoprotein antagonist for 4 days in 96-microwell plates (Flow Laboratories, Irvine, CA). Viability was assayed by trypan-blue dye exclusion. MTT assay was performed according to the manufacturer's specifications (Boehringer Mannheim).
Flow cyfornetric analysis. For analysis of cellular differentiation, expression of cell surface antigens was studied by two-color direct immunofluorescence staining technique. Cells were incubated for 60 minutes with human AB serum (Sigma) to block Fc receptors and then were stained by using fluorescein isothiocyanate (FITC)-conjugated mouse antihuman CD14 and phycoerythrin-conjugated mouse antihuman CD1 Ib (both from Becton Dickinson, Mountain View, CA), For P-glycoprotein detection, indirect immunostaining was performed after blocking the Fc receptors by human AB serum; cells were stained with monoclonal antibody MRK16 (Kyowa Medex CO, Ltd. Tokyo, Japan)," followed by staining with goat antimouse second antibody conjugated to FITC. Control studies were performed with a nonbinding control murine IgG, and IgG,, isotype antibodies (Becton Dickinson). Analysis of fluorescence was performed on a FACScan flow cytometer (Becton Dickinson).
RNA isolation and Northern blotting. Total RNA was extracted by acid guanidinium thiocyanate-phenol-chloroform method.*' Total RNA (20 pg/lane) was electrophoresed on formaldehyde-agarose gels (GIBCO-BRL) and was transferred to nitrocellulose membranes (Hybond N+; Amersham Japan, Tokyo, Japan)." Briefly, the labeled probes were hybridized for 16 to 24 hours in 50% formamide, 2X SSC ( I X SSC = 1 50 mmol/L NaCl and I5 mmol/L sodium citrate [pH 7.0]), SX Denhardt's, 0.1% sodium dodecyl sulfate, and 10% dextran sulfate (Sigma). Filters were washed to a stringency of 0 . 1 X SSC at 65°C and were exposed to Kodak XAR film (Eastman Kodak. Rochester, NY). Autoradiograms were exposed for 3 days.
Molecular pruhes. A human c-rnyc cDNA probe (EcoRI-EcoRI; 2.2 kb) was purified from plasmid pSRT 18/19 (a gift from Japanese Cancer Research Resoursers Bank, Tokyo, Japan)." Migration-inhibitory factor-related protein-8 (MRP-8) and MRP-14 cDNA probes were constructed by polymerase chain reaction (PCR) of first-strand cDNA from I ,25-dihydroxyvitamin D,-treated HL-60 cells, and details have been described previously." The @-actin probe was EcoRIBamHl(0.7-kb) fragment from plasmid pHFbA-3'.'' All probes were labeled with [ U -~~P I~C T P (3,000 Ci/mmol; Amersham) by random priming kits (Takara Shuzo CO, Ltd, Tokyo).
Revrrse-trunscriytiorz PCR (RT-PCR) assay for CYPIAI and MDR-I expression. Expression of CYPlAl and MDR-I gene was investigated by the RT-PCR method. The RT reaction was performed using 1 pg of total RNA, 100 pmol of random hexamer (BoehringerMannheim, Indianapolis, IN), 10 U RNase inhibitor (Promega, Madison. WI), 200 U Moloney murine leukemia virus-RT (GIBCO-BRL), and deoxynucleotides (final concentration, 0.5 mmollL each; Phannacia, Tokyo, Japan) in a total volume of 20 pL and under conditions recommended by the suppliers. After cDNA synthesis, 30 cycles of PCR was sequentially performed using CYPIAI, MDR-I , and @-actin primers to generate 423-bp, 243-bp. and 838-bp fragments, respectively. The primers used in this study were as follows: for CYPl AI, sense 5'-TCA CAG ACA GCC TGA TTG AG-3' (residues 928-947) and antisense 5'-GAT GGG TTG ACC CAT AGC TT-3' (residues 134 I -1360)"; for MDR-I , sense 5'-AAG CTT ACT ACC AAA GAG GCT CTG-3' (residues 2041-2064) and antisense 5'-GGC TAG AAA CAA TAG TGA AAA CAA-3' (residues 2260-2282)'"; and for @-actin, sense S'-ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CG-3' (residues 294-325) and antisense: 5'-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC-3' (residues 1100-1 131).27 PCR was performed using denaturing steps at 95°C for I minute, annealing steps at 55°C for 1 minute, and extending steps at 72°C for 2 minutes, respectively. At the end of 30 cycles, further extension for 7 minutes at 72°C was included. All reactions were performed in a total volume of 50 pL containing 2 pL of cDNA (of 20 pL total RT reaction), I mmol/L of each primer, 200 mmol/L of each deoxynucleotide, 10 mmoVL Tris HCI (pH 8.3), 50 mmol/L KCI, 2.5 mmol/L MgCI2, and 0.5 U Taq DNA polymerase (Perkin Elmer-Cetus, Norwalk, CT). PCR products ( I O pL) were electrophoresed on 2% NuSieve/l% SeaKem agarose (FMC, Rockland. MI) gels and visualized by staining with ethidium bromide. The specificity of PCR amplification was also examined by Southern blotting of the amplified cDNA with hybridization to nonradioactive probes (ECL 3'-oligolabeling and detection system; Amersham).
Assays for aryl hydrocarbon (henzo[a]pyrene) hydroxyluses in leukemic cells. Microsomal fractions of leukemic cells were purified as previously described, and protein content was determined by using bovine serum albumin as the standard.2x Incubation mixture consisted of nicotinamide adenine dinucleotide phosphate (0.8 mmollL), glucose 6-phosphate (8 mmoVL), glucose 6-phosphate dehydrogenase ( l IU), MgCI2 (6 mmol/L), NaKP buffer (pH 7.4; 100 mmol/L), EDTA (0.1 mmolk), leukemic cell microsomes (0.88 mg), and 0. I mmol/L benzo[a]pyrene as a substrate in a total volume of I mL. The reaction was started by adding @-nicotinamide adenine dinucleotide phosphate hydrogenase-generating system and was reacted at 37°C for 60 minutes. The activity of aryl hydrocarbon hydroxylases (AHHs) was quantitated using synthetic 3-hydroxybenzo[a]pyrene as the standard."' use only. 
RESULTS
Morphological changes induced in RA-resistant leukemic cells cultured with ATRA and either clotrimazole or verapamil. The RA-resistant HL-60 cells were cultured for 4 days in serum-free medium containing IO-' mol& ATRA with or without clotrimazole (IO-' mol/L) or verapamil (IO-' mol/L). Exposure of RA-resistant HL-60 cells to ATRA and either clotrimazole or verapamil resulted in differentiation towards mature granulocytes (Fig l ) . The leukemic cells from retinoid-resistant APL patients also differentiated to mature granulocytes but only after being cultured with ATRA (IO-' mol/L) and either the cytochrome P450 inhibitor or the P-glycoprotein antagonist (Fig l) . However, neither clotrimazole nor verapamil alone induced differentiation of RA-sensitive or RA-resistant leukemic cells into either mature granulocytes or monocytes (Fig l) .
Functional evidence for differentiation of RA-resistant leukemic cells to granulocytes. Induction of differentiation of RA-resistant HL-60 cells into mature granulocytes by ATRA and either clotrimazole or verapamil was assessed by the expression of CD1 Ib and CD14 antigens (Fig 2A) . Each of the chemicals individually did not alter the expression of CD1 Ib antigen by fluorescence-activated cell sorter (FACS) analysis as compared with that of control cells. In marked contrast, the combination of various concentrations of ATRA plus lo-" mol/L clotrimazole or verapamil increased the expression of CD1 Ib antigen by 6-to IO-fold as compared with that with either chemical alone (Fig 2A) . However, expression of CD14 antigen was unchanged after exposure to each of the chemicals alone or to the combination of ATRA and either clotrimazole or verapamil. Clotrimazole or verapamil alone did not affect the expression of CD1 Ib and CD14 antigens in RA-sensitive HL-60 cells (Fig 2B) . These results were consistent with the morphological changes in RA-resistant leukemic cells.
Modulation qf c-mvc and MRP-8/14 mRNA expression by ATRA and either clotrimazole or verapamil in RA-resistant leukemic cells. Studies have shown that exposure of HL-60 cells to ATRA decreased accumulation of c-myc mRNA; thus, c-myc is one of the genetic markers for cellur differentiation. Therefore, we examined the abilities of the combination of ATRA and either clotrimazole or verapamil to modulate expression of c-myc mRNA in RA-resistant HL-60 cells (Fig 3) . RA-resistant HL-60 cells were cultured for 4 days in the presence of ATRA (IO-' mol/L) and IO-' mol/L of either clotrimazole or verapamil. Accumulation of c-myc mRNA decreased after the cells were exposed to ATRA and either verapamil or clotrimazole. The combination of the above three chemicals had the most potent effect in decreasing levels of c-myc mRNA (Fig 3, lane 7) .
We have previously reported that the expression of MRPs and their transcripts were regulated during the differentiation of myeloid cells.'' Therefore, we also examined the modulation of MRP-8/14 mRNAs in RA-resistant HL-60 cells (Fig  3) . Untreated or ATRA-, clotrimazole-, or verapamil-treated cells did not express detectable levels of either MRP-8 or 
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MRP-l4 mRNA. However, MRP-8 and MRP-14 mRNAs were upregulated in the presence of ATRA and cytochrome P450 inhibitor and/or P-glycoprotein antagonist (Fig 3) . These results indicated that MRP mRNAs were expressed during granulocytic differentiation of RA-resistant HL-60 cells.
Effects of ATRA and clotrimazole andor verapamil on cell survival and proliferation of RA-resistant leukemic cells. The RA-resistant HL-60 cells were cultured for 4 days in serum-free medium containing lo-' molL of ATRA and mol/L of verapamil or clotrimazole or both of them. When added separately to culture, neither ATRA (lo-' mol/ L) nor lo-' molL of either clotrimazole or verapamil affected either the number of viable cells or the absorbance of the MTT assay, which is a nonradioactive cellular proliferation assay system ( Figs 4A, B, columns 2 through 4) . However, the combination of ATRA (IO-' mol/L) and either clotrimazole or verapamil mom) inhibited the cellular proliferation of the RA-resistant HL-60 cells (Figs 4A and B, columns 5 and 6). Moreover, the combination of clotrimazole, verapamil, and ATRA showed additive effects in inhibiting cellular proliferation ( Figs 4A and B, column 7) .
Cytochrome P450 contents in leukemic cells. To detect the cytochrome P450 in leukemic cells, we measured cytochrome P450 activity as AHH a~tivity.~' Studies have reported that no detectable basal AHH activity occurs in HepG2 hepatoma cells; however, activity of this enzyme was markedly induced in these cells after treatment with 3-methyl~holanthrene.~" After isolation of microsomes, measurements showed that levels of AHH activity in both wildtype and RA-resistant HL-60 cells were 2.29 pmol/mg/h and 2.88 pmol/mg/h, respectively (Fig 5A) .
We next examined the expression of cytochrome P450 mRNA (Fig SB) . These results were also confirmed by Southern blotting of the RT-PCR products using a probe specific for CYPlAl gene (Fig SB) .
E.rpressior1 of P-glycoprotein c u d MDR-I mRNA in leltkenric cells.
To examine the expression of P-glycoprotein recognized by monoclonal antibody MRK 16. FACS analysis was performed. Exprcssion of P-glycoprotein was low in both RA-resistant (RS HL-60) and wild-type HL-60 cells; however. it was slightly higher in RS HL-60 as compared with that in wild-type HL-60 cells (Fig 6) . To increase the sensitivity of detection of expression of the MDR-I gene in leukemic cells.
we examined the expression of MDR-I mRNA by RT-PCR technique. The MOLT-YTMQ200 cells were a positive control of MDR-I gene ( Fig 6B) . As shown in Fig 6R, RA-rcsistant HL-60 cells and leukemic cells from two RA-resistant APL patients were positive for MDR-I transcripts: however. we could not detect MDR-I mRNA in wild-type HL-60 cells and RA-sensitive APL cells.
729

DISCUSSION
Recently, ATRA has been used to induce complete remission of a high proportion of patients with APL, although their clinical remissions are usually of brief duration and they develop RA-resistant disease." Relapse and acquired resistance to treatment with ATRA in the patients with APL has been hypothesized to result from alteration of drug metabolism and from increased expression of several proteins related to RA metabolism.",'J In this study, we showed that RA-resistant HL-60 cells and fresh RA-resistant leukemic cells from APL patients differentiated to mature granulocytes when cultured with both ATRA and either a cytochrome P450 inhibitor or a P-glycoprotein antagonist.
Therefore, these two proteins (cytochrome P4.50, P-glycoprotein, or related proteins) may have an important role for the altered metabolism of RA in the development of resistance of leukemic cells.
Several possible mechanisms have been proposed to explain in vitro resistance to retinoids. One possible mechanism is the result of molecular alterations of the RA receptor (RAR) genes. Several RA-resistant HL-60 subclones have been investigated and reported to have a point mutation of the RAR-a gene. APL patients who relapsed after a remission was induced by ATRA could achieve a second remission by retinoid." Moreover, the point mutations of the RAR-cr gene detected in the RA-resistant HL-60 cells developed under the artificial conditions of the continuous exposure to high concentrations of RA ( 2 10"' mol/L).'" In contrast, the clinically administered ATRA is rapidly cleared from plasma, with a half-life of about 40 minutes and peak concentrations of less than IO-" mol/L for only 1 to 2 hours."
Another potential mechanism for clinical resistance to RA
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is pharmacological alterations in the metabolism of ATRA. use only.
For personal at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From 4-hydroxy-RA, which is oxidized readily to 4-keto-RA. The 4-hydroxylation of RA is mediated by a cytochrome P450-dependent mono-oxygenase system in vitro.'' Thus, induction of cytochrome P450 enzymes may result in lowering intracellular levels of active retinoids in leukemic cells. Treatment with cytochrome P450 inhibitors such as ketoconazole and liarozole could reduce the accelerated catabolism of retinoids and increase the mean plasma ATRA concentrations in patients with APL and other cancers. 35 We showed that the combination of ATRA and nonspecific cytochrome P450 inhibitor, clotrimazole, could induce differentiation of RA-resistant HL-60 cells and fresh RA-resistant APL cells into mature granulocytes in vitro. Also, this combination markedly decreased cellular proliferation of the cells. However, contrary to expectations, we could not detect the increased levels of cytochrome P450 activity as measured by AHH activity in RA-resistant leukemic cells. Moreover, levels of AHH activity in wild-type HL-60 cells were very low and almost equal to those present in RA-resistant cells. The cytochrome P450 superfamily consists of several enzymes, and at least 19 forms are responsible for the metabolism of foreign substrates in humans.36 A recent study has shown that an RAR-response element is present in the promoter region of the CYPl A 1 geneq7; thus, by RT-PCR method, we examined the expression of the CYPIAl gene in the leukemic cells. No CYPlAl transcripts were detectable in either RA-sensitive or RA-resistant leukemic cells, although CYPlAl is considered to be a form expressed ubiquitously in body tissues." These results suggest that AHH activity is not related to RA metabolism and the CYPlAl gene is not a major factor in the rapid catabolism of retinoids in RAresistant leukemic cells. Further studies will be needed to identify the isoform of cytochrome P450 related to RA metabolism by using specific cytochrome P450 inhibitors and more detailed molecular analyses in leukemic cells.
The other catabolic pathway of RA may involve an interaction of lipid hydroperoxides in cancer patients. Recent studies have shown that RA can be oxidized to inactivate metabolites by lipid Thus, the imidazoles such as clotrimazole generate the lipid hydroperoxides that may be involved RA metabolism.
Studies have shown that resistance to multiple chemotherapeutic agents is related to the expression of P-glycoprotein, a transmembrane drug efflux pump that is encoded by MDRl.'6.'7 In addition, the P-glycoprotein is an energy-dependent efflux pump for various lipophilic compounds'"; thus, we speculated that retinoids might be involved in this transportation system and decreased intracellular accumulation of RA may occur in RA-resistant leukemic cells. Combination of ATRA and the P-glycoprotein antagonist, verapamil, but neither of them alone, induced morphological and functional differentiation of RA-resistant leukemic cells. Although we could detect only low level of P-glycoprotein in both RA-sensitive and RA-resistant HL-60 cells, the RAresistant leukemic cells expressed MDRI mRNA, but the RA-sensitive leukemic cells did not. To measure the low and heterogenous levels of expression of MDRl/P-glycoprotein, the PCR-based method might be more reliable and sen- ~itive.~" A recent study showed significantly lower P-glycoprotein expression in APL than in other types of AML?'"2 These results suggest that a metabolic pathway of retinoids might exist that depends on P-glycoprotein and whose abnormal expression may be responsible in part for retinoid resistance in leukemic cells.
From our results and previous studies, several possible mechanisms of retinoid resistance may occur in leukemic cells (Fig 7) . Based on these findings, a couple of strategies are possible to overcome RA resistance in APL patients. To date, most approaches have not yet been successful in overcoming RA resistance in vivo. This might indicate a redundancy and complexity of the biological mechanisms of retinoid resistance. Therefore, the combination of several approaches may be effective for the treatment of patients with RA-resistant APL. For example, we have shown that the simultaneous exposure of a cytochrome P450 inhibitor and a P-glycoprotein antagonist with ATRA showed surprisingly potent ability in inhibiting proliferation and inducing differentiation of RA-resistant leukemic cells.
In summary, retinoid resistance is a serious problem of differentiation-inducing therapy for patients with APL as well as for patients with other cancers. The data presented in this report strongly suggest that acquired resistance to RA may be explained in part by the drug metabolism in leukemic cells. Moreover, the combination of ATRA and cytochrome P450 inhibitors andor P-glycoprotein antagonists might be able to overcome the resistance to RA in APL and a variety of cancers. use only.
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